Heptares eyes promise of the East as it seeks out new partnerships
This article was originally published in Scrip
Heptares Therapeutics has already established a solid link with Japan through its G-protein coupled receptor (GPCR) drug discovery collaboration with Takeda signed nearly a year ago, which seems to have piqued the attention of other potential partners in the country.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.